CytomX (CTMX) Shares Promising Early Results for CRC Drug Candidate

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the 10 Best Performing Penny Stocks So Far in 2025. On May 12, CytomX Therapeutics, Inc. (NASDAQ:CTMX) shared encouraging interim Phase 1 data for CX-2051, its EpCAM PROBODY ADC candidate, in advanced, late-line colorectal cancer (CRC).

The findings were based on data collected as of April 7, 2025, from the ongoing CTMX-2051-101 Phase 1 study.

As part of this trial, 23 patients were treated with three different doses. These were the 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses. Out of these, 18 patients could be assessed, having had a minimum of one post-baseline tumor assessment as of the data cutoff.

According to the report by CytomX Therapeutics, Inc. (NASDAQ:CTMX), CX-2051 was generally well-tolerated with manageable side effects, with no observed dose-limiting toxicities.

CX-2051 is showing strong and durable anti-tumor activity in late-line metastatic CRC, which is a very hard tumor to treat. Sean McCarthy, D. Phil, CEO and chairman of CytomX Therapeutics, Inc. (NASDAQ:CTMX), noted that this is an area that has high unmet needs.

Overall, CX-2051 has been generally safe, which highlights the potential of CytomX Therapeutics, Inc.’s (NASDAQ:CTMX) special PROBODY masking technology.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is a clinical-stage, oncology-focused biopharmaceutical company focused on developing masked biologics that conditionally activate in the tumor microenvironment.

While we acknowledge the potential of CTMX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.